Dangerous drugs update: Recent studies link GlaxoSmithKlin’s Zofran to an increased risk of several serious birth defects.
Zofran is a prescription drug approved for treatment of nausea and vomiting in surgical and chemotherapy patients. While it has never been approved by the FDA to treat morning sickness in early pregnancy, GlaxosmithKline allegedly encouraged this “off label” use of the drug. GlaxoSmithKline paid $3 billion to settle allegations by the U.S. Justice Department that the company illegally marketed Zofran for this off label use and paid doctors to prescribe it for morning sickness.
A Danish study of nearly 900,000 women determined that use of Zofran during the first trimester doubled the baby’s risk of being born with serious heart defects such as atrial septal and ventricular septal defects, and increased the child’s chances of being born with a cleft lip or cleft palate 2.4 fold. In addition, that study linked fetal growth restriction, jaundice, kidney defects in the infant to maternal use of Zofran.
Because most morning sickness and vomiting occurs during the first trimester of pregnancy, women who were prescribed Zofran used the drug at the time their developing fetus was most vulnerable to develolpment of deformities.
Zofran joins a list of dangerous drugs, such as Zoloft, Celexa, Effexor, Paxil and Topomax – all of which have been linked to birth defects.
If your child was born with a heart defect, cleft lip or cleft palate, and you were prescribed one of the drugs linked to these birth defects, your child may have a claim. Contact the Ohio Pharmaceutical Injury Attorneys at Clark, Perdue & List,